论文部分内容阅读
目的探讨肺腺癌患者血浆microRNA-10b(miR-10b)与临床特征的关系及其作为肺腺癌肿瘤标志物的可行性。方法 46例肺腺癌患者(肺腺癌组)与42例体检健康者(对照组),采用实时荧光定量PCR检测2组血浆miR-10b水平,分析miR-10b与肺腺癌临床特征间关系。绘制ROC曲线,评估miR-10b的诊断效能。结果肺腺癌组血浆miR-10b水平(1.632(0.836,2.313))较对照组(0.497(0.221,0.766))上调3.284倍(P<0.01);miR-10b表达在淋巴结转移上差异有统计学意义(P<0.05),在肿瘤原发灶情况、TNM分期上差异无统计学意义(P>0.05);miR-10b为1.212时,诊断肺腺癌的敏感性为64.3%,特异性为82.4%,AUC为0.765。结论肺腺癌患者血浆miR-10b表达明显上调,miR-10b有望成为肺腺癌的早期诊断标志物。
Objective To investigate the relationship between plasma microRNA-10b (miR-10b) and clinical features in patients with lung adenocarcinoma and its feasibility as a tumor marker for lung adenocarcinoma. Methods Forty-six patients with lung adenocarcinoma (lung adenocarcinoma group) and 42 healthy controls (control group), real-time fluorescent quantitative PCR was used to detect plasma miR-10b levels in two groups, and the relationship between miR-10b and the clinical features of lung adenocarcinoma . ROC curves were drawn to assess the diagnostic efficacy of miR-10b. Results Compared with the control group (0.497 (0.221,0.766)), the level of miR-10b in lung adenocarcinoma group was up-regulated by 3.284 folds (P <0.01). The difference of miR-10b expression in lymph node metastasis was statistically significant (P <0.05). There was no significant difference in TNM stage between the two groups (P> 0.05). The sensitivity and specificity of miR-10b at 1.212 were 64.3% and 82.4 %, AUC 0.765. Conclusion The expression of miR-10b in plasma of patients with lung adenocarcinoma is obviously up-regulated, and miR-10b may be an early diagnostic marker of lung adenocarcinoma.